- New Publication: Racial Difference in Detection Rate of Bladder Cancer Using Blue Light Cystoscopy
- Photocure Partner Asieris announces positive international Phase III clinical trial results for Cevira and data presentations at the 2024 EUROGIN Congress and SGO Annual Meeting
- Photocure Partner Asieris to present First-ever Results of the international multicenter Phase III clinical Study for Cevira, a non-surgical treatment for cervical HSIL, at the 2024 EUROGIN
- Photocure ASA: Results for the fourth quarter of 2023
Key statistics
On Wednesday, Photocure ASA (PHO:OSL) closed at 55.00, 35.14% above the 52 week low of 40.70 set on Aug 25, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 56.10 |
---|---|
High | 56.10 |
Low | 54.50 |
Bid | 55.00 |
Offer | 55.50 |
Previous close | 55.50 |
Average volume | 114.06k |
---|---|
Shares outstanding | 27.12m |
Free float | 26.68m |
P/E (TTM) | 7,660.17 |
Market cap | 1.49bn NOK |
EPS (TTM) | 0.0072 NOK |
Data delayed at least 15 minutes, as of Mar 27 2024.
More ▼